Research demonstrates that spint1-as1 suppresses gastric cancer growth through mir-656-3p and plcx3d interactions, indicating new therapeutic targets.
In the study of gastric cancer (GC), long non-coding RNAs (lncRNAs) have been identified and their functions have been partly characterized; however, the specific function of SPINT1 antisense RNA 1 (SPINT1-AS1) in GC remains unclear. This study aimed to investigate the role of SPINT1-AS1 in GC cells and elucidate its downstream molecular mechanisms. SPINT1-AS1, microRNA-656-3p (miR-656-3p), and phospholipase C, X domain containing 3 (PLCXD3) levels were modulated in GC cells through transfection experiments. Quantitative reverse transcription polymerase chain reaction and Western blot analyses were performed to assess SPINT1-AS1, miR-656-3p, and PLCXD3 levels. The proliferative capacity, apoptosis, invasion, migration, and oxidative stress levels of GC cells were evaluated using 5-ethynyl-2'-deoxyuridine assay, colony formation assay, flow cytometry, Transwell assays, and commercial kits, respectively. Dual-luciferase reporter assay and RNA immunoprecipitation assay were conducted to assess the targeting relationships among SPINT1-AS1, miR-656-3p, and PLCXD3. The impact of SPINT1-AS1 on GC tumor growth was examined in xenograft tumor models. SPINT1-AS1 and PLCXD3 were found to be downregulated in GC, whereas miR-656-3p was upregulated. SPINT1-AS1 elevation inhibited GC cell proliferation, invasion, migration, and oxidative stress, and promoted apoptosis. SPINT1-AS1 knockdown had opposite effects. The pro-tumor effects induced by SPINT1-AS1 knockdown were reversed by concomitant knockdown of miR-656-3p. Similarly, the inhibitory effects of SPINT1-AS1 elevation on GC malignancy were abrogated by PLCXD3 knockdown. SPINT1-AS1 knockdown suppressed GC tumor growth in mice. SPINT1-AS1 competitively bound to miR-656-3p to mediate PLCXD3 expression. SPINT1-AS1 suppresses GC malignancy through the regulation of the miR-656-3p/PLCXD3 axis. These findings provide robust data supporting the biological functions of lncRNAs in GC and offer potential targets for therapeutic intervention.
No takes yet. Share an insight, caveat, or question.
Duo et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: